Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes

Atherosclerosis

Volumn 206, Issue 1, 2009, Pages 134-140

  Kourimate, Sanae ^a   Chétiveaux, Maud ^a   Jarnoux, Anne Laure ^a   Lalanne, Florent ^a   Costet, Philippe ^a,b  

^a INSERM   (France)

^b L INSTITUT DU THORAX   (France)

Author keywords

Enzyme; Hepatocyte; LDLr; Mutation; PCSK9

Indexed keywords

ENZYME VARIANT; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; RECOMBINANT PROTEIN; SERINE PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; CELL LYSATE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEGRADATION; ENZYME REGULATION; ENZYME RELEASE; ENZYME SPECIFICITY; EXPRESSION VECTOR; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; VALIDATION PROCESS; WESTERN BLOTTING; WILD TYPE;

ANIMALS; HEPATOCYTES; HUMANS; MICE; SERINE ENDOPEPTIDASES;

EID: 69249245353     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.02.012     Document Type: Article

References (20)

1. Costet P., Krempf M., and Cariou B. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci 33 (2008) 426-434
2. Lagace T.A., Curtis D.E., Garuti R., et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 116 (2006) 2995-3005
3. Rashid S., Curtis D.E., Garuti R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc Natl Acad Sci USA 102 (2005) 5374-5379
4. Zaid A., Roubtsova A., Essalmani R., et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48 (2008) 646-654
5. Abifadel M., Varret M., Rabes J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34 (2003) 154-156
6. Cohen J.C., Boerwinkle E., Mosley Jr. T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006) 1264-1272
7. Maxwell K.N., Fisher E.A., and Breslow J.L. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci USA 102 (2005) 2069-2074
8. Naureckiene S., Ma L., Sreekumar K., et al. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys 420 (2003) 55-67
9. Cunningham D., Danley D.E., Geoghegan K.F., et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 14 (2007) 413-419
10. Piper D.E., Jackson S., Liu Q., et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 15 (2007) 545-552
11. Benjannet S., Rhainds D., Essalmani R., et al. NARC-1/PCSK9 and Its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 279 (2004) 48865-48875
12. McNutt M.C., Lagace T.A., and Horton J.D. Catalytic activity is not required for secreted PCSK9 to reduce LDL receptors in HepG2 cells. J Biol Chem 282 (2007) 20799-20803
13. Pandit S., Wisniewski D., Santoro J.C., et al. Functional analysis of sites within PCSK9 responsible for hypercholesterolemia. J Lipid Res 49 (2008) 1333-1343
14. Schippers I.J., Moshage H., Roelofsen H., et al. Immortalized human hepatocytes as a tool for the study of hepatocytic (de-) differentiation. Cell Biol Toxicol 13 (1997) 375-386
15. Costet P., Cariou B., Lambert G., et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory-element binding protein 1c. J Biol Chem 281 (2006) 6211-6218
16. Kourimate S., Le M.C., Langhi C., et al. Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem 283 (2008) 9666-9673
17. Lalanne F., Lambert G., Amar M.J., et al. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res 46 (2005) 1312-1319
18. Langhi C., Le M.C., Kourimate S., et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett 19 (2008) 949-955
19. Naoumova R.P., Tosi I., Patel D., et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 25 (2005) 2654-2660
20. Hampton E.N., Knuth M.W., Li J., Harris J.L., Lesley S.A., and Spraggon G. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci USA 104 (2007) 14604-14609